Last reviewed · How we verify
Triptorelin embonate 22.5 mg
At a glance
| Generic name | Triptorelin embonate 22.5 mg |
|---|---|
| Also known as | Decapeptyl, Pamorelin |
| Sponsor | Ipsen |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
- Fatigue
- Hot flashes
- White blood cell decreased
- Neutrophil count decreased
- Alopecia
- Hot flush
- Hypertension
- Anemia
- Cough
- Dysgeusia
- Rash maculo-papular
- Upper respiratory tract infection
Key clinical trials
- Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (PHASE2, PHASE3)
- Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT (PHASE2)
- Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate (PHASE3)
- Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate (PHASE3)
- GP Extended Action Triptorelin (PHASE4)
- Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate Cancer (PHASE3)
- A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR) (PHASE2)
- SRT Versus SRT+ADT in Prostate Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triptorelin embonate 22.5 mg CI brief — competitive landscape report
- Triptorelin embonate 22.5 mg updates RSS · CI watch RSS
- Ipsen portfolio CI